Washington University School of Medicine

Digital Commons@Becker
Open Access Publications

2016

Regulators of complement activity mediate
inhibitory mechanisms through a common
C3b‐binding mode
Federico Forneris
University of Pavia

Jin Wu
Utrecht University

Xiaoguang Xue
Utrecht University

Daniel Ricklin
University of Pennsylvania

Zhuoer Lin
University of Pennsylvania
See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Recommended Citation
Forneris, Federico; Wu, Jin; Xue, Xiaoguang; Ricklin, Daniel; Lin, Zhuoer; Sfyroera, Georgia; Tzekou, Apostolia; Volokhina, Elena;
Granneman, Joke CM; Hauhart, Richard; Bertram, Paula; Liszewski, M. Kathryn; Atkinson, John P.; Lambris, John D.; and Gros, Piet,
,"Regulators of complement activity mediate inhibitory mechanisms through a common C3b‐binding mode." The EMBO
Journal.35,10. 1133-49. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5895

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Authors

Federico Forneris, Jin Wu, Xiaoguang Xue, Daniel Ricklin, Zhuoer Lin, Georgia Sfyroera, Apostolia Tzekou,
Elena Volokhina, Joke CM Granneman, Richard Hauhart, Paula Bertram, M. Kathryn Liszewski, John P.
Atkinson, John D. Lambris, and Piet Gros

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5895

Published online: March 24, 2016

Article

Regulators of complement activity mediate
inhibitory mechanisms through a common
C3b-binding mode
Federico Forneris1,†, Jin Wu1, Xiaoguang Xue1, Daniel Ricklin2, Zhuoer Lin2, Georgia Sfyroera2,
Apostolia Tzekou2, Elena Volokhina3, Joke CM Granneman1, Richard Hauhart4, Paula Bertram4,
M Kathryn Liszewski4, John P Atkinson4, John D Lambris2 & Piet Gros1,*

Abstract
Regulators of complement activation (RCA) inhibit complementinduced immune responses on healthy host tissues. We present
crystal structures of human RCA (MCP, DAF, and CR1) and a smallpox virus homolog (SPICE) bound to complement component C3b.
Our structural data reveal that up to four consecutive homologous
CCP domains (i–iv), responsible for inhibition, bind in the same
orientation and extended arrangement at a shared binding
platform on C3b. Large sequence variations in CCP domains explain
the diverse C3b-binding patterns, with limited or no contribution
of some individual domains, while all regulators show extensive
contacts with C3b for the domains at the third site. A variation
of ~100° rotation around the longitudinal axis is observed
for domains binding at the fourth site on C3b, without affecting
the overall binding mode. The data suggest a common
evolutionary origin for both inhibitory mechanisms, called decay
acceleration and cofactor activity, with variable C3b binding
through domains at sites ii, iii, and iv, and provide a framework for
understanding RCA disease-related mutations and immune
evasion.
Keywords complement; regulators of complement activity; cofactor activity;
decay-accelerating activity; immune evasion
Subject Categories Immunology; Structural Biology
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Introduction
The complement system is an important arm of the humoral
immune system in mammals (Sjoberg et al, 2009; Ricklin et al,

1
2
3
4

2010; Merle et al, 2015a,b). Activation of the complement leads to
C3b opsonization of targeted cells and particles inducing killing and
clearance of the target. To protect host cells and tissues from inadvertent complement activation, mammals express complement regulators, such as factor H (FH), complement receptor 1 (CR1, CD35),
membrane-cofactor protein (MCP, CD46), and decay-accelerating
factor (DAF, CD55; Zipfel & Skerka, 2009; Merle et al, 2015a). These
regulator proteins stop C3b opsonization by breaking down the C3
convertases. Lack of protection, due to familial mutations in the
complement genes (Liszewski & Atkinson, 2015a; MartinezBarricarte et al, 2015) or the presence of autoantibodies against
regulators (Luzzatto & Gianfaldoni, 2006; Dragon-Durey et al,
2010), has been linked to, for example, atypical hemolytic uremic
syndrome (aHUS) and C3 glomerulopathies (C3G) in kidneys and
age-related macular degeneration (AMD) in eyes. Moreover, conditions of chronic and acute inflammations, as in rheumatoid arthritis,
strokes, and heart attacks, become aggravated by complement activation against the disturbed tissue (Sjoberg et al, 2009; Merle et al,
2015b). These pathological conditions underscore the importance of
balancing complement activation and regulation (Ricklin & Lambris,
2013a).
Proteins of the “regulators of complement activation” (RCA)
gene cluster consist of strings of consecutive complement control
protein (CCP) domains of ~60–70 amino-acid residues (Kirkitadze &
Barlow, 2001). Complement regulators CR1, MCP, and DAF are
expressed on cell membranes, where they provide immediate
protection to host cells. The soluble regulator FH stops complement
activation in the fluid phase and discriminates “self” from “nonself” cells and matrix material by binding host molecular patterns
(Clark et al, 2013). The protective function can be attributed to 3–4
consecutive CCP domains (Kirkitadze & Barlow, 2001; Zipfel &
Skerka, 2009; Merle et al, 2015a), which may act through two
inhibitory mechanisms. DAF, CR1, and FH have so-called decayaccelerating activity. Decay acceleration enhances the irreversible
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dissociation of protease fragments from C3 convertases, either
C4b2a or C3bBb (Nicholson-Weller & Wang, 1994; Hourcade et al,
1999). Linked to this first activity, the regulators also block the binding of proenzymes and prevent the formation of new convertases.
MCP, CR1, and FH exert cofactor activity. By binding to C3b or C4b,
these regulators provide a binding platform for the protease factor I
(FI). Bound FI cleaves C3b and C4b to yield fragments that cannot
form convertases. Viruses and bacteria utilize these host protection
mechanisms to avoid complement response. While certain bacteria
express surface-bound proteins that bind host FH to provide protection (Zipfel et al, 2013; Merle et al, 2015b; Schmidt et al, 2015),
orthopox and herpes viruses encode their own protection proteins,
which structurally and functionally mimic host regulators (Ahmad
et al, 2007; Ojha et al, 2014). Variola virus “smallpox inhibitor of
complement enzymes” (SPICE) consists of four CCP domains and
exhibits both decay-accelerating and cofactor activities (Rosengard
et al, 2002) and is 40% identical in amino-acid sequence to human
MCP.
A structural basis of regulator binding to C3b was provided by
crystal structures of C3b in complex with FH domains CCP1–4 (Wu
et al, 2009) and C3d in complex with FH CCP19–20 (Kajander et al,
2011; Morgan et al, 2011). The structure of C3b-FH CCP1–4 shows
C3b in its characteristic arrangement of a key-ring-shaped core
consisting of 6 macroglobulin domains (MG1–6) connected by a
linker domain, two domains (MG7–8) on top of the key ring that
connect to an arm formed by a “complement C1r/C1s, UEGF,
BMP1” (CUB) domain and thioester-containing domain (TED); and
a C-terminal C345c (CTC) domain at the top of C3b (Janssen et al,
2006; Wiesmann et al, 2006; see Fig 1). The FH CCP1–4 binding site
spans C3b from the a0 N-terminal (a’NT) region bound to MG7,
through MG6, MG2, and CUB, down to MG1 and TED. The C-terminal CCP19–20 domains of FH bind at a distinct binding site
provided by the TED domain. Taken together, “mini-FH” chimeras
consisting of the CCP1–4 and 19–20 showed strong decay-accelerating and cofactor activities, similar to those of full-length FH
(Hebecker et al, 2013; Schmidt et al, 2013). Structure comparison of
C3b-FH CCP1–4 and the C3 convertase (C3bBb) in complex with
SCIN (Rooijakkers et al, 2009) suggested that FH displaces Bb by
steric hindrance upon binding to C3b, thereby exerting its decayacceleration activity. Furthermore, crystal structures of FB in
complex with C3b or the homologous cobra-venom factor (CVF;
Janssen et al, 2009; Forneris et al, 2010) revealed overlapping binding sites for the CCP1–2 domains of FB and the CCP1–2 domains of
FH, which explains why binding of FH to C3b blocks convertase
formation. In the case of cofactor activity, regulator binding to C3b
provides a binding platform for the protease FI. Roversi et al
presented a crystal structure of FI (Roversi et al, 2011) and
suggested that FI possibly binds at a niche formed by the regulator
domains CCP1–3 of FH and the CTC domain of C3b, providing a
potential explanation for the regulator role in cofactor activity of
FH.
Regulators vary in activity and C3b- and C4b-binding behavior,
even though all regulators consist of strings of homologous CCP
domains (Kirkitadze & Barlow, 2001; Ahmad et al, 2007; Harris
et al, 2007; Zipfel & Skerka, 2009; Merle et al, 2015a). Both MCP
and DAF require their CCP3–4 for binding to C3b (Liszewski et al,
2000; Harris et al, 2007) and CCP2–4 for cofactor activity (Liszewski
et al, 2000; Riley et al, 2002) and decay-accelerating activity,
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respectively (Harris et al, 2007). However, their CCP2–4 domains
map to CCP2–4 and CCP1–3 of FH, respectively (McLure et al,
2004). CR1 bears three clusters of CCP domains displaying differential C3b/C4b binding and associated regulatory activities. The
CCP1–3 domain binds weakly to C3b and strongly to C4b (Krych
et al, 1991) and predominantly shows decay acceleration in both
classical and alternative pathways (Krych-Goldberg et al, 1999),
whereas the two domain clusters CCP8–10 and CCP15–17, identical
in sequence with the exception of four amino acids, bind strongly to
both C3b and C4b (Krych et al, 1994) and display mostly cofactor
activity (Krych et al, 1994, 1998). Furthermore, FH and CR1 binding
to C3b depends on interactions with the a’NT region, whereas MCP
does not (Lambris et al, 1996; Krych et al, 1998; Oran & Isenman,
1999; Makou et al, 2013). Extensive mutagenesis data for MCP
(Liszewski et al, 2000) show that C3b binding of domain CCP4 of
MCP is incompatible with the observed arrangement of the equivalent domain in C3b-FH CCP1–4 complex (Wu et al, 2009). Various
mutations of regulators linked to aHUS, C3G, and AMD have been
reported (Weisman et al, 1990; Zipfel & Skerka, 2009; Rodriguez
et al, 2014; Liszewski & Atkinson, 2015b; Schramm et al, 2015).
These mutations identify multiple sites on the surface of C3b, FH,
MCP, and CR1 responsible for effective complement regulation. The
available structural data from the C3b-FH (CCP1–4; Wu et al, 2009)
and C3d-FH (CCP19–20; Kajander et al, 2011; Morgan et al, 2011)
complexes and the structures of isolated regulators (Smith et al,
2002; Uhrinova et al, 2003; Williams et al, 2003; Lukacik et al,
2004; Persson et al, 2010) provided initial guidance for structural
mapping of these mutations. However, the differences in the
sequences and structural orientations of the various CCP domains of
the regulators did not provide an unambiguous molecular explanation for several disease-related mutations (Dragon-Durey &
Fremeaux-Bacchi, 2005; Rodriguez et al, 2014; Liszewski & Atkinson, 2015b; Martinez-Barricarte et al, 2015; Schramm et al, 2015).
In addition, Gropp et al (2011) indicated b2-glycoprotein I, which
consists of five CCP domains, to act as a complement regulator
(Gropp et al, 2011). To provide a structural basis for binding of the
regulators and their activities, we determined the crystal structures
of human DAF domains CCP2–4, MCP CCP1–4, CR1 CCP15–17, and
the variola virus SPICE (full-length CCP1–4) in complex with human
C3b. In addition, we report the structure of “free” C3b at 2.8-Å resolution, thereby improving the resolution of an earlier report
(Janssen et al, 2006). These data indicate a common binding site on
C3b for the regulators and suggest a common structural origin for
the complement-inhibitory activities by the “regulators of complement activation (RCA)”.

Results and Discussion
Structural data
We determined the crystal structures of C3b-MCP (CCP1–4), C3bSPICE (CCP1–4), C3b-CR1 (CCP15–17), and C3b-DAF (CCP2–4) to
2.4, 2.5, 3.3, and 4.2-Å resolution, respectively (Table 1 and
Fig 1A). Previously, we reported the crystal structure of C3b-FH
(CCP1–4) at 2.7-Å resolution (Wu et al, 2009). For these fragments,
we observed KD’s of 0.35 lM for MCP (CCP1–4), 1.3 lM for SPICE
(CCP1–4), 1.9 lM for CR1 (CCP15–17), 6.1 lM for DAF (CCP1–4),
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Figure 1. Structural overview of C3b-regulator complexes.
A From left to right, surface representation of the three-dimensional structures of C3b-MCP (CCP1–4) (blue), C3b-SPICE (CCP1–4) (green), C3b-FH (CCP1–4) (orange),
C3b-CR1 (CCP15–17) (dark red), C3b-DAF (CCP2–4) (purple).
B Cartoon representation of the five regulators. The width of the cartoon is proportional to the B-factors observed in the structural data. The B-factor coloring (from
blue to red) is in relative scale according to the resolution of the crystal structures.
C Cartoon representation of the five C3b molecules in the C3b-regulator complexes. Coloring and style as in (B).
D Highlight of electron density maps (2Fo-Fc, blue, contour level 1.2r; Fo-Fc, green and red, contour level 3r and 3r, resp.) for the regions of the C3b-regulator
complexes showing flexibility. From left to right: the putative site for MCP CCP2, SPICE CCP4, CR1 CCP15, and DAF CCP2.

and 7.2 lM for FH (CCP1–4); see Fig EV1. Furthermore, initial crystallization trials of C3b-CR1 (CCP15–17) and C3b-b2GPI yielded
crystals containing only C3b. One of these crystals was used to

ª 2016 The Authors

collect a C3b data set up to 2.8-Å resolution, superseding the C3b
structure at low resolution currently available in the PDB (Janssen
et al, 2006).
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Table 1. Diffraction, data collection, and refinement statistics.
C3b-DAF (CCP2–4)

C3b-CR1 (CCP15–17)

C3b-MCP (CCP1–4)a

C3b-SPICE (CCP1–4)

C3b

Space group

P21221

P1

P21221

P1

P21

Cell parameters

a = 117.4 Å
b = 142.4
Å c = 323.7 Å

X-ray source

ESRF ID14 EH4

ESRF ID23 EH1

ESRF ID29

ESRF ID14 EH4

ESRF ID14 EH4

Data processing
software

iMOSFLM/SCALA

iMOSFLM/SCALA

iMOSFLM/AIMLESS

XDS/AIMLESS

iMOSFLM/AIMLESS

Wavelength (Å)

0.975

0.873

0.933

0.939

0.939

Resolution (Å)

117.83–4.20
(4.43–4.20)

60.15–3.30
(3.48–3.30)

69.95–2.40
(2.44–2.40)

47.80–2.50
(2.55–2.50)

70.07–280
(2.89–2.80)

Molecules per ASU

2

2

1

1

1

Unique reflections

39,033 (5,369)

88,061 (12,811)

98,854 (4,722)

84,531 (4,525)

109,359 (9,703)

Data collectionb

a = 90.0°
b = 90.0°
c = 90.0°

a = 104.3 Å
b = 113.7
Å c = 138.5 Å

a = 82.7°
b = 71.8°
c = 80.9°

a = 82.8 Å
b = 130.6
Å c = 233.8 Å

a = 90.0°
b = 90.0°
c = 90.0°

a = 68.9 Å
b = 83.3 Å
c = 127.4 Å

a = 75.0°
b = 76.2°
c = 68.5°

a = 57.6 Å
b = 136.5 Å
c = 140.9 Å

Redundancy

4.1 (3.9)

1.9 (1.9)

3.8 (2.9)

2.0 (1.9)

2.1 (2.1)

I/r(I)

6.3 (2.3)

3.8 (1.4)

6.8 (2.0)

4.3 (1.0)

9.4 (1.5)

Completeness (%)

96.5 (92.6)

98.4 (98.2)

99.0 (96.2)

97.2 (96.3)

96.8 (98.3)

CC1/2

n.d.

n.d.

0.988 (0.693)

0.963 (0.527)

0.954 (0.685)

Rmeasc

0.175 (0.673)

0.225 (0.878)

0.116 (0.583)

0.128 (0.774)

0.122 (1.098)

0.258/0.296

0.250/0.291

0.188/0.219

0.198/0.229

0.229/0.268

Overall

192

143

67

80

107

C3b only

189

137

67

78

107

Regulator only

218

179

73

100

N/A

a = 90.0°
b = 96.1°
c = 90.0°

Refinement
Rwork/Rfree
2

Average B-factors (Å)

27,275

27,406

13,810

14,478

12,150

Protein

27,275

27,378

13,123

14,036

12,122

Ligands
(including glycans)

0

28

195

235

28

Waters

0

0

492

207

0

Bond lengths (Å)

0.005

0.003

0.005

0.004

0.003

Bond angles (°)

1.04

0.83

0.85

0.88

0.65

Favored (%)

93

96

97

96

96

Allowed (%)

6

4

2

3

4

Disallowed (%)

1

0

1

1

0

Number of atoms

R.M.S. deviations

Ramachandran statistics

In the crystal structure of C3bMCP (CCP1–4), only CCP domains 3 and 4 could be modeled.
b
Values in parentheses are for reflections in the highest resolution shell.
c
Rmeas = Σhkl {n/[n - 1]} 1/2 × Σi | I - 〈 I 〉 |/Σhkl Σi I, where I is the observed intensity for a reflection and 〈 I 〉 is the average intensity of symmetry-related
observations of a unique reflection.
a

C3b-regulator arrangements
The regulators bound to C3b show extended arrangements of their
CCP domains, while C3b displays its characteristic organization of
MG1–8, linker, CUB, TED, and CTC domains (Janssen et al, 2006,
2005; Wiesmann et al, 2006; Fig 2A). The extended CCP arrangements are in agreement with the structures of unbound regulators
and regulator fragments (Smith et al, 2002; Uhrinova et al, 2003;
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Williams et al, 2003; Lukacik et al, 2004; Persson et al, 2010;
Appendix Fig S3). Overall, the regulators bind C3b at the same
site, formed by the a’NT region and domains MG7, MG6, CUB,
MG2, MG1, and TED (top to bottom as shown in Fig 2A), similar
to that observed in the complex of C3b with FH CCP1–4 (Wu
et al, 2009). The C3b-regulator contact interfaces extend over a
length of up to 130 Å burying surface areas up to 2,300 Å2 (see
Fig 2 for details).
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A

B

Figure 2. Domain organization in the C3b-regulator complexes and molecular interactions.
A “Open-book” surface representation of C3b and regulator molecules, highlighting their domain organizations using different colors as shown in the neighboring
schemes. Domains in complement regulators are labeled using domain numbering from CCPi to CCPiv based on their contact sites on C3b. The corresponding CCP
domains in each regulator described in this work are shown in the bottom-left scheme. Domains CCP1–2 of MCP are shown in shaded gray because they are not
involved in C3b binding. The table reports the extent of the regulator contact surface on C3b and the associated buried surface area.
B Opened view of the molecular footprint of the regulator-C3b interaction (as shown in Fig 2A), highlighting the C3b domains on the regulator surface (top) and the
regulator domains on C3b (bottom).

ª 2016 The Authors
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C3b-MCP differs markedly from C3b-FH CCP1–4 in two aspects.
First, in C3b-MCP, only CCP3–4 makes contact with C3b. No density
and non-interpretable density were observed for CCP1 and CCP2,
respectively (Fig 1D), whereas the density was well resolved for the
CCP3 and CCP4 domains of MCP (Appendix Fig S1). These observations are in agreement with biochemical data that CCP1 and CCP2
of MCP do not contribute to C3b binding (Adams et al, 1991).
Second, the orientation of MCP CCP4 differs markedly from FH
CCP4. Though MCP CCP4 domain binds at the same site to C3b, it is
rotated by ~100° around the long axis of the domain compared to
CCP4 of FH in C3b-FH (Fig 3A and B, Appendix Fig S4A). Figure 3C
shows that mutagenesis data on CCP4 of MCP (Liszewski et al,
2000) is in full accordance with the observed domain orientation in
the crystal structure. The competitive binding of the GB24 antibody
to MCP, identified by mutagenesis around residues Phe230 and
Phe242, further supports the observed MCP interaction site
(Liszewski et al, 2000). The CCP4 domain of SPICE binds C3b in the
same orientation as MCP CCP4, although the electron density for
SPICE CCP4 was weak, indicating disorder and suggesting weak
local interactions (Fig 1D). Limited contribution by SPICE CCP4 to
C3b binding is supported by improved binding of vaccinia virus
complement control protein (VCP) CCP1–3 fused to MCP CCP4
(Ahmad et al, 2010). Putatively, FH may be considered deviant from
MCP and SPICE. FH may have evolved differently due to its subsequent domains that function in specific host-surface recognition
(Clark et al, 2013).
Most C3b-regulator contacts involve the central CCP domains,
that is, MCP CCP3–4, SPICE CCP2, FH CCP2–4, CR1 CCP16–17, and
DAF CCP3–4 (Table 2), which correspond with areas of low
B-factors (Fig 1B and C). The N-terminal domains, CCP1 of FH,
CCP15 of CR1, and CCP2 of DAF, make only minor contacts to a’NT
and MG7 at the C-terminal “bottom” side. These domains point
outwards from the complexes and show variable orientations. The
non-crystallographic symmetry copies of DAF CCP2 differ by 17°,
resulting in a ~20 Å displacement, consistent with flexibility at the
CCP2-CCP3 hinge of DAF (Appendix Fig S4A; Uhrinova et al, 2003).
Overall, SPICE differs from the other regulators with low B-factors
for CCP1–2 and high B-factors for the bottom side of CCP3 and the
complete CCP4 domain (Fig 1B). Crystal contacts of SPICE CCP1
contribute to the local packing resulting in lower B-factors
(Appendix Fig S2B). SPICE CCP3–4 domains pack against C3b-like
CCP3–CCP4 of MCP (Fig 3A and B); however, these interactions
appear to be weaker and the interactions with C3b are dominated
by contacts through domains CCP1–2 of SPICE. The C-terminal
CCP4 domains of MCP and FH interact extensively with C3b
(though MCP and FH use distinct interaction faces of CCP4 in binding to C3b). For MCP, all contacts with C3b involve CCP3–4 only
(Table 2, Fig EV2). Thus, marked differences in C3b-regulator
contacts and CCP order–disorder are observed, which in part reflect
the differences in interactions made by the CCP domains for binding
to C3b.
C3b structural variations
The C3b structures in all regulator complexes display the typical
domain organization of C3b (Appendix Fig S4B). Notably, CUB-TED
and CTC show variable positioning with respect to the main body of
C3b. The characteristic b-ring of C3b (Fig 2A) can be divided into a
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bottom (MG1, 4–5) and top part (MG2–3, 6) with flexibility for the
bottom part that is higher as observed in C3b-SPICE and
the unbound C3b at 2.8-Å resolution compared to that observed in
the other presented structures (Fig 1C, Appendix Fig S4D). Variations in CUB-TED and CTC positions and between the b-ring top
and bottom parts were previously observed in C3bB, C3bBD
(Forneris et al, 2010) and the SCIN-stabilized C3bBb convertase
(Rooijakkers et al, 2009), in its bovine ortholog (Fredslund et al,
2006), and in paralogs such as alpha-2-macroglobulin (Marrero
et al, 2012), C5 (Fredslund et al, 2008), and the C5b-C6 complex
(Aleshin et al, 2012; Hadders et al, 2012).
The CTC domain of C3b adopts different orientations with the
“neck” that links CTC to the MG core found in two distinct conformations. This neck region (residues 1,496–1,517) connects CTC to
MG8 through the main chain and participates in three disulfide
bonds; one internal (Cys1506–Cys1511) and one each connecting to
MG7 (Cys873–Cys1513) and to the CTC domain (Cys1518–Cys1590;
Appendix Fig S5). During conversion from C3 to C3b, this region
undergoes a complete change of its secondary structure. In C3, residues 1,507- to 1,517-fold into a a-helix (Janssen et al, 2005;
Fredslund et al, 2006). In unbound C3b, the internal disulfide bond
connects two short b-strands (respectively, 1,503–1,508 and 1,509–
1,515) that fold into a short b-turn-b configuration (Janssen et al,
2006; Wiesmann et al, 2006). This conformational change positions
CTC in a more upward orientation, while the MG7-MG8-CUB
arrangement does not change (Appendix Fig S5). In the structures
of C3b-SPICE, C3b-CR1, and C3b-DAF, the neck region adopts the
b-turn-b configuration (Appendix Fig S5), as for all reported C3b
structures except C3b-FH CCP1–4 (Janssen et al, 2006; Wiesmann
et al, 2006; Katschke et al, 2009; Rooijakkers et al, 2009; Wu et al,
2009; Forneris et al, 2010; Garcia et al, 2010). The same conformational change is observed for conversion from C4 to C4b (Kidmose
et al, 2012; Mortensen et al, 2015) and from C5 to C5b (Fredslund
et al, 2008; Aleshin et al, 2012; Hadders et al, 2012). In the C3bMCP and C3b-FH structures, the neck region adopts the a-helical
configuration and is almost identical to that observed in C3. In these
structures, the CTC shows a pronounced downward orientation
(Fig EV3A). In this down position, a protruding loop of CTC (residues 1,585–1,600) contacts CUB, with aromatic residues Phe1558
and Trp1612 of CTC surrounding CUB residue Pro972 (Appendix Fig
S6B). This arrangement is similar to the CTC-CUB contact observed
in native C3. In C3b, the CTC loop docks on the b-hairpin conformation of the neck region through p-p stacking of the aromatic residues
with Arg1507 and Arg1512 (Appendix Fig S6B). Since MCP, CR1
(CCP15–17), and FH have strong cofactor activity, the observed
arrangements of CTC in C3bFH (CCP1–4) and C3bMCP (CCP1–4)
may possibly reflect a preferred conformational arrangement for
binding of FI; however, this arrangement is not observed for
C3bCR1 (CCP15–17).
Besides the variations in C3b CTC positions (Fig EV3A), we
observe differences in the placement of CUB and TED domains
(Fig EV3B–D). The series of structures can be separated into two
sets that differ by ~6–9 Å in CUB position as shown for residues
1,311–1,317 (Fig EV3C and D). Structures of C3b-DAF (CCP2–4)
and C3b-CR1 (CCP15–17) show CUB-TED, with high B-factors, positioned in a downward orientation, while C3b-FH, C3b-MCP, and
C3b-SPICE have CUB-TED in an upward position (Fig EV3B). The
largest distinction between these two sets of structures is the
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Figure 3. Molecular features of C3b-bound MCP and SPICE and comparison with C3b-FH.
A Superposition of MCP and FH domains CCP3–4 (shown as blue and orange cartoons, respectively) on the surface of C3b.
B Cartoon representation of the superposition of domains CCP3–4 of MCP (blue), FH (orange), and SPICE (green). Despite the strong structural similarity and the
conserved angle between domains CCP3 and CCP4, MCP and SPICE show a rotation of approximately 100° in the position of CCP4 compared to FH.
C The reported mutagenesis data on MCP CCP3 and CCP4 (data from Liszewski et al, 2000) are consistent with the crystal structure. Shown are two orientations of the
surface of MCP CCP3–4 as in the crystal structure of the C3b-MCP complex, highlighting the contact sites with the C3b platform (purple), the MCP mutations
identified as critical for C3b binding (red) and those not affecting the interaction (blue). The GB24 antibody epitope is shown as yellow contour on the MCP surface.
D Model of the putative positioning of the flexible CCP1–2 domains of MCP. The model has been generated by superposing the structure of CCP1–4 of MCP from PDB
3O8E (Persson et al, 2010) onto the structure of the C3b-MCP (CCP1–4) complex. CCP1–2 domains of MCP, not visible in the C3b-MCP (CCP1–4) structure, are shown
in gray.
E Highlight of the primary sequence differences between SPICE and VCP. The 11 mutations distinguishing the two viral regulators are shown on the surface of SPICE in
purple. The contact surface of C3b on the regulator in the C3b-SPICE (CCP1–4) complex is shown in green on the right panel.

presence of a CCP domain binding to the MG1-TED site on C3b.
With CUB-TED in the up position, more interactions between CUB
and MG2 domains are observed forming a more tightly packed
concave interface for interactions with the regulators (Fig EV3B–D).
Additional hydrogen-bonding and salt-bridge interactions between
these two domains involve the side chains of Arg979 with main
chain carbonyl of Leu198, Arg937 with Glu226, Lys930 with
Glu197, a proximate interaction (not forming hydrogen bonds in the
structures) between Ser1315 and Gln177, and the main chain nitrogen of Leu1319 with the carbonyl of Pro174 of CUB and MG2,
respectively (Appendix Fig S6A). Moreover, the upward orientation
of CUB-TED facilitates the possible interactions with loop 1,607–
1,622 of CTC. However, both up and down positions are observed
in the two structures of (unbound) C3b and that of other C3b
complexes (Janssen et al, 2006; Wiesmann et al, 2006; Katschke
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et al, 2009; Rooijakkers et al, 2009; Wu et al, 2009; Forneris et al,
2010; Garcia et al, 2010). This indicates that the energy difference
between the two forms is small. The CUB-TED domains in the
structure obtained at 2.8-Å resolution (reported here) are better
packed (as judged by the B-factors and crystal contacts) and are
placed in the up position. In the previously reported structure at 4-Å
resolution (Janssen et al, 2006), these domains are in the down
position with higher B-factors. Overall, the ~6–9 Å upward
movement of CUB-TED observed for FH, MCP, and SPICE is likely
induced by concerted bridging contacts between MG2 and CUB with
the C-terminal part of CCP3 and contacts between the N-terminal
part of CCP4 with TED. Together, these contacts result in a
rearrangement of C3b domains MG2, CUB, and TED that has
recently been indicated as critical for the strong cofactor activity of
these regulators (Gautam et al, 2015).

The EMBO Journal Vol 35 | No 10 | 2016

1139

Published online: March 24, 2016

The EMBO Journal

Structures of C3b-complement regulators complexes

Federico Forneris et al

Table 2. Summary of interactions details between C3b and regulators, divided by CCP domaina.

Buried surface
area (Åb)c

Number of
contacting
amino acids

Number of
electrostatic
contactsd

Number of
strong
hydrophobic
contactse

C3b-MCP (CCP1–4)

C3b-SPICE (CCP1–4)

C3b-FH (CCP1–4)

C3b-CR1 (CCP15–17)b

C3b-DAF (CCP2–4)b

CCP1: 0

CCP1: 311

CCP1: 419

CCP15: 284

CCP2: 230

CCP2: 0

CCP2: 533

CCP2: 537

CCP16: 802

CCP3: 303

CCP3: 443

CCP3: 374

CCP3: 643

CCP17: 865

CCP4: 843

CCP4: 774

CCP4: 522

CCP4: 741

Total: 1217

Total: 1740

Total: 2340

Total: 1951

Total: 1376

CCP1: 0

CCP1: 40

CCP1: 55

CCP15: 34

CCP2: 13

CCP2: 0

CCP2: 70

CCP2: 61

CCP16: 83

CCP3: 36

CCP3: 53

CCP3: 51

CCP3: 68

CCP17: 98

CCP4: 95

CCP4: 88

CCP4: 58

CCP4: 80

Total: 141

Total: 219

Total: 264

Total: 215

Total: 144

CCP1: 0

CCP1: 2

CCP1: 7

CCP15: 2

CCP2: 1

CCP2: 0

CCP2: 9

CCP2: 2

CCP16: 7

CCP3: 1

CCP3: 8

CCP3: 3

CCP3: 11

CCP17: 12

CCP4: 15

CCP4: 16

CCP4: 6

CCP4: 9

Total: 24

Total: 20

Total: 29

Total: 21

Total: 17

CCP1: 0

CCP1: 5

CCP1: 9

CCP15: 7

CCP2: 3

CCP2: 0

CCP2: 13

CCP2: 13

CCP16: 18

CCP3: 5

CCP3: 13

CCP3: 10

CCP3: 20

CCP17: 23

CCP4: 26

CCP4: 23

CCP4: 11

CCP4: 20

Total: 36

Total: 39

Total: 62

Total: 48

Total: 34

Values reported are obtained from computational analyses using the PISA software (Krissinel & Henrick, 2007).
b
For the C3b-CR1 (CCP15–17) and C3b-DAF (CCP2–4) structures, the values reported refer to averages between the two copies in the asymmetric unit.
c
Values for buried surface area are defined as sum of areas from C3b and regulator.
d
Electrostatic contacts defined as sum of residues involved in hydrogen bonds and salt bridges.
e
Number of strong hydrophobic contacts defined as the sum of residues showing buried area percentages higher than 40% according to PISA interface analysis.
a

Interactions between C3b and CCP domains: sites i–ii
The N-terminal CCP domains interact with C3b only through residues from their C-terminal “bottom” and linker to the next, second
CCP domain (generic CCP domains and their binding sites are
referred to as CCPi-CCPiv, see Fig 2A). This CCPi–ii site constitutes
a contiguous surface that interacts with a small hydrophobic patch
surrounded by negatively charged residues from the a’NT region
and MG7 domain on C3b (Fig EV4). The domains binding to this
a’NT-MG7 site (SPICE CCP1, FH CCP1, CR1 CCP15, and DAF CCP2)
differ by rigid-body rotations of 2–12° in the various complexes
(Appendix Fig S4C). The diversity in domain positions yields large
variations among the specific contacts observed in the C3b-regulator
structures (as summarized in Fig EV2). DAF almost completely
lacks hydrophobic interactions at this site, and the differences
between the two C3b-DAF copies observed in crystal structure indicate weak binding of the regulator to this site (Appendix Fig S2).
Previous mutagenesis data (Appendix Table S1) identified a group
of amino-acid residues in DAF (located at its CCP2–CCP3 linker) as
critical for decay-acceleration activity (Kuttner-Kondo et al, 2001).
Among these, a group of positively charged residues R134-R135K160 interacts with the a’NT of C3b in one of the two copies
observed in the C3b-DAF (CCP2–4) crystal structure. In the other
copy, the displacement of DAF CCP2 does not allow any contacts of
this domain with C3b (Appendix Fig S2). In agreement with our
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data and interpretation, DAF CCP2 is not required for binding DAF
to C3b (Harris et al, 2007), replacement of VCP CCP1 with DAF
CCP2 resulted in loss of C3b binding for VCP (Ahmad et al, 2010),
and the DAF CCP2–3 domain orientation is flexible, as shown by
NMR (Uhrinova et al, 2003; Appendix Fig S3E). In contrast, rigidity
in the domain–domain arrangement was indicated based on NMR
structures of CR1 CCP15–16 and CCP16–17 (Smith et al, 2002),
structures of related C3b-binding domains CR1 CCP1–2 and CCP2–3
(Park et al, 2014), and solution studies of CR1 (Furtado et al, 2008;
Appendix Fig S3D). CR1 CCP15 shows limited but very specific
interactions at this site, which are mostly localized around the loop
proximate to the a’NT and the C-terminus of the CCP15 domain.
These contacts constitute the specific anchoring point for CR1
CCP15–16 to the C3b platform and are consistent with previous
reports (Lambris et al, 1996; Oran & Isenman, 1999). CR1 contacts
with C3b at this site include the hydrophobic interactions surrounding CCP15 Tyr978 with a’NT Ile756 and MG7 Phe920, as well as the
hydrogen bond between CCP15 Arg 980 and a’NT Asp754 (although
observed only in one of the two independent complexes in the crystal). The multiple contacts observed for C3b-FH and C3b-SPICE
involve few conserved and several non-conserved interactions at
this site, among which electrostatic interactions and hydrophobic
contacts located between the CCP1–2 interface and a’NT as well as
CCP2 and MG6. These contacts include the conserved charged interaction between FH Arg83 (Arg84 in SPICE) with a’NT Glu759, the
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Figure 4. Structural mapping of disease-related mutations on the C3b-regulator surfaces.
A Mapping of known disease-related mutations on C3b (Appendix Table S4). The high-resolution C3b three-dimensional structure is used as structural template, shown
as white surface. The regulator contact surfaces (based on C3b-FH (CCP1–4; Wu et al, 2009) and C3d-FH (CCP19–20; Kajander et al, 2011; Morgan et al, 2011)) are
shown as black contour. All mutations reported in Appendix Table S4 are shown in blue on the C3b surface. Disease-related mutants reported to affect regulator
binding are shown in red and labeled in the right magnified panel.
B Mapping of disease-related mutations on the FH (CCP1–4) surface using data from Appendix Table S5. Colors as in (A).
C Mapping of disease-related mutations on the MCP (CCP3–4) surface using data from Appendix Table S5. Colors as in (A).

hydrophobic region defined by FH Pro84-Gly86 (Arg85-Pro87 in
SPICE) proximate to Val762, the conserved CCP2 residue Asp90
(Asp91 in SPICE) forming a hydrogen bond with MG6 Lys796, and
the hydrophobic groove defined by FH Phe96, Leu98, and Phe104
(Leu97, Ile99, and Val102 in SPICE, respectively) with MG6 Phe794
(Fig EV2).
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Interactions between C3b and CCP domains: sites ii and iii
Next, the regulator domains superposing on to FH CCP2 and CCP3
interact with domains MG2, MG6, and CUB of C3b (Fig EV2). These
interactions involve polar and charged amino-acid side chains and
main chain carbonyl and amino moieties of C3b MG2 forming
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hydrogen bonds with the regulator domains. In particular, the
b-strand formed by residues 175–186 of MG2 exposes several negative charges that form an elongated binding site, which is involved
in interactions as observed in all C3b-regulator structures (Fig EV2).
A fully conserved interaction is observed for main chain NH of residue
Ser181 in C3b with the main chain CO of the regulator’s residue
preceding a sharp turn, that is, Gly171 in FH, Gly169 in SPICE,
Leu184 in MCP, Gly1088 in CR1, and Arg246 in DAF. On the regulator side facing the CUB domain, amino-acid residues interacting
with CUB surround residue Arg1310 of C3b, whose side chain points
toward negatively charged residues (Glu177 in MCP, Glu163 in FH,
Glu1083 in CR1) or aromatic side chains (Tyr162 in SPICE). In addition, highly variable interaction sub-sites are observed and are
summarized in Fig EV2. Few disease-related mutations of C3 have
been reported that map on the regulator binding sites formed by
MG2 and MG6. The known mutations, R592W/Q, R161W, and
T162R, are located on the periphery of the CCPii–iii binding regions
in C3b. This CCPii–iii binding site is, however, also involved in
interactions with FB at two steps in the convertase formation
(Janssen et al, 2009; Rooijakkers et al, 2009; Forneris et al, 2010,
2012). First, in the “loading” state, FB binds C3b with its CCP2 in a
position that overlaps with FH CCP2 (Janssen et al, 2009;
Rooijakkers et al, 2009). Second, in the “activation” state of C3bB,
the helical extension of the FB-serine protease domain covers the
FH CCP3 binding site (Fig EV5; Forneris et al, 2010). Mutations in
the CCPii–iii binding regions may thus affect both FB and FH
binding to C3b. Disturbing FB binding would likely reduce or stop
complement activation and, if binding of FB to C3b is still intact,
disturbing FH binding would lead to uncontrolled, that is, more,
complement activation. Possibly, the central role of FB binding to
C3b in complement activation limits the number of disease-related
mutations observed in the overlapping FB and regulator binding
sites (CCPii-CCPiii) on MG2/6 of C3b.
Mutagenesis experiments on CR1 CCP clusters provided details
for the putative C3b/C4b binding sites and for the residues implicated in decay-accelerating and cofactor activities (Krych et al,
1991, 1994, 1998; Krych-Goldberg et al, 1999, 2005). A summary
of this comprehensive analysis is provided in Appendix Table S2
and Appendix Fig S7A–C. Consistent with our structural data, all
mutations significantly affecting C3b binding in CCP8–10 and
CCP15–17 map onto the C3b-CR1 (CCP15–17) interface observed
in the crystal structure and are localized at C3b binding sites. Also
the mutations affecting C3b/C4b binding on the CCP1–3 domains
of CR1 (Appendix Table S2A) entirely map to this region. The most
prominent differences between the CCP1–3 and CCP8–10, and
CCP15–17 clusters are all located at the C3b-CR1 (CCP15–17) interface (Appendix Fig S7A–C). Furthermore, the epitope for the 3D9
antibody, responsible for abolishing the CR1-C3b binding (Krych
et al, 1998), overlaps with the contact site between C3b and CR1
at the bottom side of CCP17 (Appendix Fig S7B). In DAF, mutagenesis data (summarized in Appendix Table S2 and Appendix
Fig S8A) show that mutations affecting decay-acceleration activity
are distributed all over the C3b-binding side of DAF, mostly
through charged residues in CCP3–4 (residues R240 and R246).
Domain swapping of CCP2 in the orthopox regulator Kaposica with
DAF CCP3 results in loss of cofactor activity of this viral inhibitor
(Gautam et al, 2015). The DAF side not involved in interactions
with C3b shows that residues critical for decay acceleration are
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clustered on the CCP2–3 domains only, consistent with the
expected binding data for the Bb fragment (Harris et al, 2007) and
data from domain swapping with MCP (Gautam et al, 2015). Mutagenesis of SPICE and the homologous VCP (Yadav et al, 2008;
Liszewski et al, 2009; Appendix Table S3) indicated that SPICE
residue Asn163 (located on CCP3) is solely responsible for a fourfold increase in C3b binding, when replaced with Glu163 in VCP
(Sfyroera et al, 2005; Yadav et al, 2008). In the C3b-SPICE (CCP1–
4) structure, this residue lies at the interface between C3b and
SPICE, in the vicinity of MG2 Asp178 side chain (although not
forming hydrogen bonds with this residue; Fig 3E). Hence, the
presence of a negatively charged residue in VCP in this position
may be responsible for the reduced binding affinity due to charge
repulsion, as initially suggested by previous computational electrostatic modeling of VCP and SPICE chimeras (Sfyroera et al, 2005).
Interactions between C3b and CCP domains: site iv
A C-terminal interaction site is observed for FH, MCP, and SPICE
CCP4 with MG1 and TED domains of C3b. As described above,
the most prominent feature of this interaction site is the marked
structural difference in the orientation of the CCP4 domains of
MCP and SPICE binding to C3b compared to FH. Moreover, the
high B-factors for C3b-SPICE at this interaction site suggest
flexibility and reduced interactions between SPICE CCP4 and C3b
in comparison with the FH and MCP. SPICE CCP4 bears numerous
negative charges at the bottom-edge of this domain in comparison
with FH and MCP (Fig EV4). Remarkably, removal of one of the
few positive charges located in the observed contact interface with
C3b at the “bottom” of VCP CCP4 (residue Lys233, corresponding
to SPICE Thr233, Fig 3E) did not affect C3b binding (Yadav et al,
2008). This observation supports the notion that SPICE CCP4
contributes less to complex formation. SPICE and the highly
homologous VCP are evolutionarily more closely related to MCP
than to other human regulators (Ciulla et al, 2005). This is in
agreement with the structural arrangement observed in C3b-SPICE
(CCP1–4), which shows strong similarity to MCP in the orientation
of the CCP3 and CCP4 domains bound to C3b (Fig 3A and B).
Whereas charged residues are broadly distributed over the whole
interaction surface of FH CCP4 providing interactions with both
MG1 and TED, MCP and SPICE are binding to C3b only through
the upper half of their CCP4 domains and only with TED, that is,
without specific interactions with the MG1 domain of C3b
(Fig EV2B).
Mapping disease-related mutations and diseasepredisposing polymorphisms
Over the years, a large number of mutations and diseasepredisposing polymorphisms associated with pathological
conditions such as aHUS, AMD, and C3G have been reported
involving C3b and/or complement regulators FH and MCP
(summarized in Appendix Tables S4 and S5). Our structures enable
precise mapping and provide a structural interpretation of the
effects for the majority of these mutations. Except for those clearly
identified as involved in binding of FH CCP19–20 (Jokiranta et al,
2000; Kajander et al, 2011; Morgan et al, 2011), all pathogenic C3b
mutations known to affect regulator-C3b binding map on residues
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located on MG1, MG2, MG6, and MG7 at or near the regulator
binding interface (Fig 4A). Our data now facilitate a structural
basis to observed functional differences between regulators due to
these mutations. C3G-related deletion mutation 923-DDG located
on MG7 of C3b (Martinez-Barricarte et al, 2010) influences the
conformation of the a’NT region. This region provides critical
contact sites for FH, whereas the structural variability observed in
the two C3b-DAF (CCP2–4) monomers found in the crystal structure of the complex indicates that this region is dispensable for
DAF binding (Appendix Fig S8B). Consistently, this mutation
impairs decay acceleration and binding by FH, but not by DAF
(Martinez-Barricarte et al, 2010). aHUS mutations Q185E/H on
MG2 (Noris et al, 2010) and R592Q on MG6 (Fremeaux-Bacchi
et al, 2008; Fig 4A) affect binding and cofactor activity of FH,
but not those of MCP nor CR1 (Schramm et al, 2015;
Appendix Table S4). In C3b-FH, these C3b mutations disrupt the
hydrogen bonds with the side chain of residue Glu116 on CCP2
(Wu et al, 2009). Such hydrogen-bonding network is not present in
C3b-MCP or C3b-CR1, as shown by the very weak and flexible
interactions of MCP CCP2, and the presence of a threonine residue
(CCP16 residue 1,033) in CR1 replacing FH Glu116 (Fig EV2B).
Mutations on regulators can be divided into two major groups in
general. One group maps onto the C3b-regulator interfaces and
likely affects interactions with C3b, whereas the second group is
located on the opposite side of the regulator and cannot be
explained by current structural data. The latter mutations likely
affect the interactions of the regulator with factor I in cofactor
activity or with the convertase fragment Bb in decay-acceleration
activity. Despite extensive studies on pathogenic mutations
of FH located on its CCP1–4 domains (summarized in
Appendix Table S5), their effects on C3b binding were only studied
for very few mutations. The V62I mutation showed increased binding affinity for C3b and enhanced cofactor activity (Tortajada et al,
2009). Pechtl et al (2011) found that aHUS mutation R78G has the
opposite effect, reducing FH binding to C3b, as well as cofactor
and decay-accelerating activity. As we already reported for the
C3b-FH (CCP1–4) crystal structure (Wu et al, 2009), this mutation
maps in the middle of the C3b-FH contact interface at the CCP1 site
(Fig 4B). In MCP, numerous pathogenic mutations leading to
aHUS and C3G phenotypes affect domains CCP3 and CCP4
(Appendix Table S5). For five of these mutations, all associated
with aHUS, binding studies report reduced C3b binding and
decreased cofactor activity (Richards et al, 2003; Caprioli et al,
2006; Fremeaux-Bacchi et al, 2006). Consistent with our structural
data, these five mutations are located at the C3b-MCP contact sites,
as shown in Fig 4C. In CR1, the only documented mutation in the
CCP15–17 region is Q1022H, which may be linked to adaptive
evolutionary events to protect individuals from cerebral malaria in
endemic regions of Asia (Birmingham et al, 2003; Thomas et al,
2005). This mutation is located on CCP16, in proximity to the
CCP15–16 linker, and is conserved in all three CR1 CCP clusters
that bind C3b (Appendix Fig S7A). Presence of this mutation
increases CR1 binding affinity to C4b but not to C3b (Birmingham
et al, 2003). In the C3b-CR1 (CCP15–17) structure, this residue is
in close proximity (approximately 6 Å) to C3b, but does not make
direct contacts with C3b (Appendix Fig S7D). Superposition with
the recently published three-dimensional structure of C4b
(Mortensen et al, 2015), however, does not suggest a straightforward
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explanation for the alteration in CR1-C4b binding affinity due to
this mutation.
Conclusions
The four presented and one previously published crystal
structures of C3b-regulator complexes show that the consecutive
CCP domains harboring the complement-inhibitory activities of
human MCP, DAF, FH, CR1, and of vaccinia virus-derived SPICE
bind in the same orientation to the same binding platform on
C3b. Nevertheless, marked deviations from the common binding
mode are apparent with differences in participation of individual
domains to the binding (consistent with biochemical data) and in
virtually all details of the interacting residues at the C3b-regulator
interface.
The largest known binding platform on C3b for regulator fragments stretches from the a’NT-MG7 site, through sites on MG6,
MG2, and CUB to MG1 and TED, as previously observed for C3b-FH
(CCP1–4; Wu et al, 2009), with an additional binding site for FH
(CCP19–20) at TED (Jokiranta et al, 2000; Kajander et al, 2011;
Morgan et al, 2011). The CCP1–CCP4 domains of FH and SPICE
bind with the N-terminal domains (CCP1) to the a’NT-MG7 site,
CCP2 to MG6-MG7, CCP3 to MG2 and CUB, and the C-terminal
CCP4 to MG1 and TED, defining the generic CCPi-CCPiv domains
and binding sites. MCP only binds through its CCP3–4 domains at
the CCPiii-CCPiv binding sites on C3b. The orientation of MCP and
SPICE CCP4 differs by 100° from that of FH however without changing the overall global binding of the extended CCP configuration
and, thus, adhering to the common binding mode. The domains
CCP2–4 of DAF and CCP15–17 of CR1 bind at the sites CCPi–iii, in
agreement with biochemical binding data (Krych et al, 1994; Harris
et al, 2007; Gautam et al, 2015). The similarity in C3b binding of
the decay-accelerating regulator DAF, cofactor–regulator MCP and
CR1 (CCP15–17), and dual-activity regulators FH and SPICE
suggests that the two distinct complement-inhibition mechanisms
(decay-acceleration and cofactor activities) may have evolved from
a common C3b-regulator binding origin. Furthermore, the strong
decay accelerator DAF binds both C3b and Bb and both binding sites
appear important for decay activity (Harris et al, 2007). However,
what the roles of the two binding sites are in the molecular mechanism of decay acceleration remains unclear. Based on sequence and
structural homologies, the regulators of the classical pathway of
complement activation (that is thought to have evolved from the
alternative pathway (Nonaka & Yoshizaki, 2004)) likely bind C4b
using the same binding mode as in C3b-regulator binding. The
extensive variations during evolution may have served to adapt
precise regulator functionality. Concatenation of the three C3b/C4b
binding sites in CR1 may provide synergistic effects (Krych-Goldberg
et al, 2005). The fluid regulator FH may have adapted its CCP4
orientation from a putative canonical orientation as observed for
MCP CCP4 and SPICE CCP4, to account for subsequent CCP
domains involved in host interactions of the soluble FH. Similarly,
the surface-bound regulators MCP and DAF may have evolved to
enhance their cofactor- and decay-acceleration activity, respectively,
at the expense of losing the potential of dual function. Thus, we
conclude that the two functional activities, decay-acceleration and
cofactor activities, are based on one common C3b-regulator binding
mode.
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Regulators with decay-acceleration and/or cofactor activity vary
in CCP domains bound to the CCPi–iv binding sites on C3b.
Biochemical data (Krych et al, 1991, 1994; Gordon et al, 1995;
Kuttner-Kondo et al, 2001, 2007; Harris et al, 2007; Wu et al, 2009;
Gautam et al, 2015) show that domains CCPi-CCPiii suffice for
decay-accelerating activity. The structural data support the observation that predominantly CCPii–iii (as for DAF CCP3–4) account for
the C3b binding interactions (Harris et al, 2007). Domains CCPi-ii
(CCP2–3) of DAF are important for binding the Bb protease fragment (Kuttner-Kondo et al, 2003; Harris et al, 2007); thus, CCPi–iii
form a minimal functional fragment in decay acceleration (KuttnerKondo et al, 2001, 2007; Harris et al, 2007). Strong cofactor activity
of MCP requires binding of only CCP3–4 to sites CCPiii–iv
(Liszewski et al, 2000; Gautam et al, 2015). Nevertheless, an associated CCPii domain is linked to cofactor activity (Krych et al, 1994,
1998; Yadav et al, 2008; Gautam et al, 2015); presumably, it is
required for binding of FI. Regulators with both decay acceleration
and cofactor activity bind C3b through CCPi up to CCPiv: This
combines C3b binding interaction at CCPi–ii for decay acceleration
and those for cofactor activity at CCPiii–iv for regulator activity.
Structures of C3b with MCP, FH, or SPICE reveal many interactions with C3b at the CCPiii binding site. At the CCPiv site, the
CCP4 domains of FH, MCP, and SPICE differ in interactions with
C3b. MCP and SPICE CCP4 bind in the same orientation and interact
with TED. FH CCP4 differs by ~100° (around the longitudinal axis)
and interacts with both MG1 and TED. The density and B-factor for
CCP4 of SPICE suggest weaker binding for SPICE at this site. In the
structures of C3b-FH (CCP1–4) and C3b-MCP, the interactions of
CCP4 with TED appear correlated with a 6–9 Å tilt of CUB-TED. In
addition, this lifting of CUB-TED facilitates interactions between
MG2, CUB, and CTC. The CUB-CTC arrangement in the latter two
C3b complexes is remarkably similar to the CUB-CTC contact in
native C3. Moreover, interactions bridging MG2-CUB induced by
regulators with cofactor activity may be critical for FI binding and
cofactor activity (Gautam et al, 2015). However, whether and
how these conformational changes affect the cofactor activity
requires structural data of the ternary complex of C3b-regulator with
a bound FI.
Our data are in good agreement with mutagenesis and functional
characterizations of regulator-C3b binding (Krych et al, 1991, 1994,
1998; Krych-Goldberg et al, 1999, 2005; Liszewski et al, 2000;
Kuttner-Kondo et al, 2001, 2007; Sfyroera et al, 2005; Harris et al,
2007; Yadav et al, 2008; Ahmad et al, 2010; Gautam et al, 2015).
Moreover, the presented structural data explain the differential
effect of C3b mutations on regulators. Depending on the location of
the mutant in the extended binding site, some but not all regulators
may be affected by that mutation (Martinez-Barricarte et al, 2010;
Schramm et al, 2015). Disease-related mutations affecting C3b-regulator interactions are located at or near the CCP interaction sites.
Most mutations are located near the CCPiv site, while CCPii and
CCPiii have less disease-related mutations known to date. The CCPii
and CCPiii sites, however, also provide a contact interface for FB in
convertase formation, both in the “loading” and “activated” conformation of FB bound to C3b (Fig EV5). Perhaps, the C3b interactions
with FB (preceding the interactions with regulators in the complement pathways) restrict the number of mutations affecting regulator
binding at the CCPii and CCPiii sites. Mutations in FH, MCP, and
CR1 affecting FI binding (Krych et al, 1991; Krych-Goldberg et al,
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1999; Liszewski et al, 2000; Rodriguez et al, 2014) or in DAF
affecting Bb binding (Kuttner-Kondo et al, 2003; Harris et al, 2007)
are distant from the observed C3b-regulator interfaces; thus, the
structural data support the interpretation that these mutation affect
either FI or Bb interactions. We could, however, not confirm previously reported C3b interactions or regulator activity for b2GPI
(Gropp et al, 2011; Fig EV1). Even though CCP1–4 of b2GPI resembles complement regulators in domain composition and overall
shape, its amino-acid composition differs markedly from complement regulators of the RCA family. In particular, the putative C3bbinding site on CCP3 displays numerous hydrophobic residues,
where regulators contain hydrophilic residues critical for C3b binding (Appendix Fig S9A). Furthermore, b2GPI Asn162 in CCP3 is
glycosylated (Bouma et al, 1999), whereas residues at the equivalent site of the regulators are interacting with C3b (Appendix Fig
S9B). Thus, the Asn162 linked glycan of b2GPI likely precludes
binding to C3b.
In summary, we have shown that C3b-regulator binding can be
classified as extensive variations on a common binding mode. We
hypothesize that one evolutionary origin may underlie this C3bregulator binding mode that facilitates both decay-acceleration and
cofactor activities in complement inhibition for host protection or
immune evasion. The data highlight how molecular mimicry may
impact infection and immunity, that is, how the evolution of structural and functional similarities of SPICE from variola virus, and
homologs from other orthopox viruses, with human RCA assists its
evasion of complement response (Ahmad et al, 2007; Ojha et al,
2014). Finally, the presented structural data will be instrumental to
characterize the functional consequences of genetic polymorphisms
(Rodriguez et al, 2014) that have been associated with pathologies
and may guide the further development of regulator-based therapeutics for the treatment of complement-mediated diseases (Ricklin &
Lambris, 2013b).

Materials and Methods
Protein production and C3b affinity measurements
Complement component C3b was obtained by isolating C3 from
fresh human plasma, followed by specific cleavage of C3 into C3b
by recombinant human factor B and factor D as described before
(Forneris et al, 2010). Iodoacetamide was used to block the nascent
thioester to prevent dimerization of C3b. The regulator fragments
were produced in E. coli, P. pastoris, and human embryonic kidney
(HEK) 293 cells. CR1 CCP15–17 (residues 942–1,136) was produced
in P. pastoris using established methods (Kirkitadze et al, 1999).
MCP CCP1–4 (residues 35–285), and full-length SPICE CCP1–4 (residues 19–263) were expressed in inclusion bodies in E. coli, refolded
and purified (Sfyroera et al, 2005; Fremeaux-Bacchi et al, 2008).
N-terminal His6-tagged DAF CCP2–4 (residues 97–285) and MCP
CCP1–4 (residues 35–285), as glycosylated alternative to the E. coli
product, were purified from medium after expression in HEK293.
Purified MCP (CCP1–4) from both E. coli and HEK293 showed
comparable activity (Fig EV1), confirming previous observations
that glycosylation at the three potential glycosylation sites does not
affect cofactor activity (Liszewski et al, 1998). Full-length b2glycoprotein I (b2GPI) and its fragment CCP1–4 were recombinantly

ª 2016 The Authors

Published online: March 24, 2016

Federico Forneris et al

Structures of C3b-complement regulators complexes

expressed in HEK293 cells. For crystallization purposes, we used
N-acetylglucosaminyltransferase I-negative HEK293 cells (HEK293-ES,
U-Protein Express B.V. Utrecht, the Netherlands; Reeves et al,
2002), which lack the ability to synthesize complex Asn-linked
glycans and hence produce short-chain, and more homogeneous,
glycosylated proteins that can be crystallized more readily. All
proteins were purified to homogeneity by either metal-affinity chromatography or ion-exchange chromatography and gel-filtration prior
to crystallization according to previously established protocols (Wu
et al, 2009; Forneris et al, 2010).
C3b binding affinity of the purified regulator proteins and protein
fragments was determined by surface plasmon resonance (SPR),
using a Biacore 3000 instrument (GE Healthcare) at 25°C. As
described previously (Schmidt et al, 2013), C3b was deposited
through its thioester moiety onto CM5 sensor chips by covalently
immobilizing a low amount of C3b (< 500 RU) on a flow cell using
standard amine coupling chemistry and amplifying C3b deposition
via multiple injection cycles of factors B and D (200 nM each) and C3
(1 lM) in HBST buffer (10 mM HEPES, 150 mM NaCl, 0.005%
Tween-20, pH 7.4) containing 1 mM NiCl2. Comparative affinity
measurements of complement regulators were performed in HBST
containing 3 mM EDTA as running buffer. Twofold serial dilutions of
MCP CCP1–4 (0.003–7 lM), both from E. coli and HEK293, FH
CCP1–4 (0.005–19 lM), CR1 CCP15–17 (0.005–11 lM), DAF CCP1–4
(0.09–50 lM), and SPICE CCP1–4 (0.003–3.5 lM) were injected for
60 s at a flow rate of 20 ll/min with a dissociation phase of 180 s.
No regeneration was required as all signals readily returned to baseline. Data were processed and analyzed in Scrubber (v2.0c; BioLogic
Software). An unmodified CM5 sensor chip flow cell was used as a
reference surface, and several buffer blank injections were
subtracted to account for buffer bulk and injection artifacts. Injection signals were normalized by dividing the SPR responses by the
molecular weight of the corresponding protein. Binding affinities
(KD) were calculated by globally fitting the processed steady state
responses of the regulators to a single-site binding model. In the
case of b2GPI, the binding activity toward C3b and the proposed
property to enhance the interaction between C3b and FH were
assessed on a CM5 sensor chip surface with covalently immobilized
C3b. For this purpose, b2GPI CCP1–4 was injected at a concentration of 500 nM for 2 min at a flow rate of 10 ll/min with a dissociation phase of 2 min. Three concentrations of FH (12.5, 25, 50 nM)
were injected under the same conditions in the presence and
absence of 500 nM b2GPI CCP1–4. The surface was regenerated by
injecting 2 M NaCl for 60 s after each cycle. The data were analyzed
using Scrubber as described above.
Protein crystallization and structure determination
Crystallizations of the C3b-regulators were performed by vapor diffusion at 18°C in 1:1 molar ratios to protein concentrations of
8–10 mg/ml. Crystals of C3b and E. coli-derived MCP (CCP1–4)
were obtained in droplets equilibrated against 100 mM ammonium
citrate, 7% w/v polyethylene glycol (PEG) 3350, 5 mM Lglutathione, and 50 mM bis-Tris propane, pH 6.5. Crystals appeared
after 2–3 days and were harvested from mother liquor solution after
1 week. Initial crystals for C3b-SPICE were obtained at 75 mM
ammonium iodide and 3.5% w/v PEG 3350, but these crystals
diffracted poorly. Well-diffracting crystals were obtained after
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seeding the initial crystal hits in fresh crystallization droplets. The
crystals appeared after few hours and continued to grow for about
1 week. First attempts to crystallize C3b-CR1 (CCP15–17) yielded
good quality crystals containing free C3b. Further experiments
yielded crystals of C3b-CR1 (CCP15–17) using a reservoir composed
of 8% w/v PEG 3350 and 35 mM bis-Tris pH 5.5. For C3b-DAF
(CCP2–4), crystals suitable for diffraction were obtained after extensive microseed-matrix screening (Till et al, 2013) in a condition
containing 60 mM MgCl2, 30 mM bis-Tris pH 5.5, 6.5% w/v
PEG 3350, and 3% v/v meso-erythritol, using sitting drop vapor
diffusion at 30°C.
All crystals were harvested using nylon cryo-loops, transferred to
reservoir solutions supplemented with cryo-protectants (20% v/v
ethylene glycol for C3b-MCP (CCP1–4), 20–25% w/v glycerol for
C3b-SPICE (CCP1–4), C3b-CR1 (CCP15–17), and C3b-DAF (CCP2–4)
and flash-frozen in liquid nitrogen for data collection. Diffraction
data were collected at beamlines of the European Synchrotron Radiation Facility (ESRF) and the Swiss Light Source (SLS; details in
Table 1) and processed using MOSFLM, XDS, and AIMLESS (Collaborative Computational Project, Number 4, 1994; Kabsch, 2010;
Battye et al, 2011). The observed resolution limits of the diffraction
data, selected by evaluating the correlations between half data sets
(CC1/2; Karplus & Diederichs, 2012), were 2.8 Å for C3b, 2.4 Å for
C3b-MCP (CCP1–4), 2.5 Å for C3b-SPICE (CCP1–4), 3.3 Å for C3bCR1 (CCP15–17), and 4.2 Å for C3b-DAF (CCP2–4). All structures
were solved by molecular replacement by Phaser (McCoy et al,
2007) using the coordinates from the crystal structures C3c minus
its CTC domain (PDB ID 2A74; Janssen et al, 2005), followed by
sequential positioning of the TED, CTC, and CUB domains obtained
from the three-dimensional structure of C3b (PDB ID 2I07; Janssen
et al, 2006). Search models for regulators were generated from the
crystal structures of MCP (CCP1–4; PDB ID 3O8E; Persson et al,
2010), DAF (CCP1–4; PDB ID 1OK3; Lukacik et al, 2004), and the
NMR structures of CR1 (CCP15–16 and CCP16–17; PDB IDs 1GKN
and 1GKG, resp.; Smith et al, 2002). Alternating cycles of automated
refinement using phenix.refine (Adams et al, 2010) and manual
model building using COOT (Emsley et al, 2010) were applied to
generate the structural models. Validation of the final structural
models was carried out using MOLPROBITY (Chen et al, 2010) and
PDB-CARE (Lutteke & von der Lieth, 2004). Complete data collection details and final model statistics are available in Table 1. In all
structures, all domains of C3b could be modeled (Appendix Fig S2).
For C3b-MCP (CCP1–4), only domains CCP3–4 of MCP could be
modeled due to lack of density for CCP1 and lack of interpretable
density for CCP2 (Fig 1D). All four CCP domains of SPICE were
modeled; however, CCP4 showed notably weak density (Fig 1D).
Two C3b-CR1 (CCP15–17) complexes were present in the asymmetric unit. The two C3b-CR1 (CCP15–17) complexes displayed minor
differences in the orientation of domain CCP15, while neither of the
two copies of CCP15 was directly involved in crystal contacts. Noncrystallographic symmetry was applied to each CCP domain of CR1
separately (excluding the linker peptides), thus allowing adjustment
of the binding orientations and positions of the CCP domains with
respect to C3b in each copy. Also for C3b-DAF (CCP2–4), two copies
of the complex were present in the asymmetric unit with significant
differences in orientation of the CCP2 and CCP3 domains. Extensive
crystal contacts between CCP2 of one copy with CCP4 of another
resulted in 17° rotation of the regulator (compared to its bound C3b)
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and a displacement of over 20 Å (as measured at the N-terminal edge
of CCP2; Appendix Fig S2A). For modeling and refinement against
the 4.2-Å resolution C3b-DAF (CCP2–4) data set, external structural
restraints were applied based on the 2.8 Å-resolution C3b structure
(this work) and the high-resolution structures of free DAF (Lukacik
et al, 2004).
Coordinates and structure factors for C3b and the complexes of
C3b-MCP (CCP1–4), C3b-CR1 (CCP15–17), C3b-DAF (CCP2–4), and
C3b-SPICE (CCP1–4) have been deposited at the Protein Data Bank
(PDB) with accession numbers 5FO7, 5FO8, 5FO9, 5FOA, and 5FOB,
respectively. For consistency, UniProt residue numberings were
used throughout, including in the deposited structure coordinates.
We refer to the sequences of UniProt database entries P01024 (C3/
C3b), P15529 (MCP), Q89859 (SPICE), P08603 (FH), P17927 (CR1),
P08174 (DAF), and P02749 (b2GPI). The reference sequence for the
vaccinia virus complement control protein (VCP) used for comparison with SPICE was UniProt entry P68638.
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